在验证性疗效试验中阐明治疗靶点与中介因素:认知行为治疗与光照治疗冬季抑郁的随机对照试验研究方案
本研究为验证性疗效试验,针对冬季季节性情感障碍,比较季节性情感障碍定制的团体认知行为治疗(CBT-SAD)与光照治疗(LT)的疗效机制。此前试验中CBT-SAD与LT治疗后转归相似,但CBT-SAD与两个冬季后抑郁复发较少相关(CBT-SAD组27.3% vs LT组45.6%)。本研究将随机分配160名成人,检测两种治疗的目标参与生物标志物,并检验复发时转换治疗的决策规则。
要点
- 研究比较CBT-SAD与LT,主要结局为抑郁复发状态,检验CBT-SAD优于LT。
- CBT-SAD与两个冬季后抑郁复发较少相关(CBT-SAD组27.3% vs LT组45.6%)。
- 通过生物标志物评估两种治疗的目标参与和中介机制。
核心结论
- 本研究旨在确认光照治疗和CBT-SAD的靶点与机制,以最大化未来推广效果,符合美国国家精神卫生研究所关于在研究领域标准相关生物标志物层面展示靶点参与的重点。
研究设计与样本
- 验证性疗效随机对照试验,目标样本量为160名季节性情感障碍成人,随机分配至6周CBT-SAD或光照治疗,第1个冬季治疗,第2个冬季随访,若抑郁复发则交叉至另一治疗,所有受试者第3个冬季随访。
- 生物标志物评估在第1个冬季治疗前、中、后,第2个冬季随访时(交叉者再次在治疗中、后评估),以及第3个冬季随访时进行。
- 主要疗效分析检验CBT-SAD在抑郁复发状态(主要结局)上优于光照治疗;中介分析使用平行过程潜增长曲线模型。
主要发现
- 此前疗效试验中,CBT-SAD与光照治疗治疗后转归非常相似,但CBT-SAD与两个冬季后抑郁复发较少相关(CBT-SAD组27.3% vs 光照治疗组45.6%)。
- CBT-SAD参与并改变了特定作用机制——季节性信念,该机制中介了CBT-SAD的急性抗抑郁效应和CBT-SAD相对于光照治疗的持久获益。
- 光照治疗的靶点和效应生物标志物包括昼夜节律相位角差和光照后瞳孔反应。
- CBT-SAD的靶点和效应生物标志物包括对季节性词语的瞳孔反应降低和持续性额叶γ波段脑电反应降低,这些被假设为季节性信念的生物标志物,反映CBT-SAD后对季节性刺激的参与减少。
临床怎么用
- 本研究检验复发时「转换」决策规则的疗效,以 inform 临床实践中的决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study is a confirmatory efficacy trial of two treatments for winter seasonal affective disorder (SAD): SAD-tailored group cognitive-behavioral therapy (CBT-SAD) and light therapy (LT). In our previous efficacy trial, post-treatment outcomes for CBT-SAD and LT were very similar, but CBT-SAD was associated with fewer depression recurrences two winters later than LT (27.3% in CBT-SAD vs. 45.6% in LT). CBT-SAD engaged and altered a specific mechanism of action, seasonal beliefs, which mediated CBT-SAD's acute antidepressant effects and CBT-SAD's enduring benefit over LT. Seasonal beliefs are theoretically distinct from LT's assumed target and mechanism: correction of circadian phase. This study applies the experimental therapeutics approach to determine how each treatment works when it is effective and to identify the best candidates for each. Biomarkers of LT's target and effect include circadian phase angle difference and the post-illumination pupil response. Biomarkers of CBT-SAD's target and effect include decreased pupillary and sustained frontal gamma-band EEG responses to seasonal words, which are hypothesized as biomarkers of seasonal beliefs, reflecting less engagement with seasonal stimuli following CBT-SAD. In addition to determining change mechanisms, this study tests the efficacy of a "switch" decision rule upon recurrence to inform clinical decision-making in practice. METHODS: Adults with SAD (target N = 160) will be randomzied to 6-weeks of CBT-SAD or LT in winter 1; followed in winter 2; and, if a depression recurrence occurs, offered cross-over into the alternate treatment (i.e., switch from LT➔CBT-SAD or CBT-SAD➔LT). All subjects will be followed in winter 3. Biomarker assessments occur at pre-, mid-, and post-treatment in winter 1, at winter 2 follow-up (and again at mid-/post-treatment for those crossed-over), and at winter 3 follow-up. Primary efficacy analyses will test superiority of CBT-SAD over LT on depression recurrence status (the primary outcome). Mediation analyses will use parallel process latent growth curve modeling. DISCUSSION: Consistent with the National Institute of Mental Health's priorities for demonstrating target engagement at the level of Research Domain Criteria-relevant biomarkers, this work aims to confirm the targets and mechanisms of LT and CBT-SAD to maximize the impact of future dissemination efforts. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03691792 . Registered on October 2, 2018.
引用
- Rohan KJ, Franzen PL, Roeckelin KA, et al. Elucidating treatment targets and mediators within a confirmatory efficacy trial: study protocol for a randomized controlled trial of cognitive-behavioral therapy vs. light therapy for winter depression. Trials. 2022. PMID: 35550645. doi:10.1186/s13063-022-06330-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。